AstraZeneca

AstraZeneca

AstraZenecaAstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com.

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US) 30 October 2018
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma 26 October 2018
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer 25 September 2018
Selumetinib granted orphan designation in Europe for neurofibromatosis type 1 09 August 2018
Atacand to be divested to Cheplapharm in Europe 24 July 2018
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease 12 June 2018
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets 07 May 2018
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors 16 March 2018
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics 02 March 2018
AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage 24 January 2018
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma 07 September 2017
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack 29 August 2017
Kyntheum approved in the EU for the treatment of adults with moderate-to-severe plaque psoriasis 20 July 2017
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig 08 June 2017
AstraZeneca enters agreement with Recordati for Seloken in Europe 22 May 2017
AstraZeneca's potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe 05 April 2017
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897 09 March 2017
Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease 24 November 2014
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund 16 May 2014
AstraZeneca and MRC enter strategic collaboration 31 March 2014